Aravax's Peanut Allergy Immunotherapy PVX108 Granted FDA Fast Track Status

Aravax's PVX108, an immunotherapy for peanut allergy, has received Fast Track designation from the U.S. Food and Drug Administration (FDA). This status recognizes the therapy's potential to address a serious, life-threatening condition with unmet medical needs, potentially accelerating its development and review process.